Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial
Vishal Patel, Sunjae Lee, Mark McPhail, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 2, pp. 332-342
Open Access | Times Cited: 139

Showing 1-25 of 139 citing articles:

Intestinal Barrier in Human Health and Disease
Natalia Di Tommaso, Antonio Gasbarrini, Francesca Romana Ponziani
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 23, pp. 12836-12836
Open Access | Times Cited: 305
Gut–liver axis: barriers and functional circuits
Oliver Pabst, Mathias W. Hornef, Frank G. Schaap, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 447-461
Closed Access | Times Cited: 149
Promises of microbiome-based therapies
Jasmohan S. Bajaj, Siew C. Ng, Bernd Schnabl
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1379-1391
Open Access | Times Cited: 71
Fecal microbiota transplantation inhibits colorectal cancer progression: Reversing intestinal microbial dysbiosis to enhance anti-cancer immune responses
Hao Yu, Xing-Xiu Li, Xing Han, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 48
Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies
Marta Maestri, Francesco Santopaolo, Maurizio Pompili, et al.
Frontiers in Nutrition (2023) Vol. 10
Open Access | Times Cited: 44
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
Mads Israelsen, Bjørn Stæhr Madsen, Nikolaj Torp, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 6, pp. 523-532
Open Access | Times Cited: 42
Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases
Susana Rodrigues, Van der Merwe, Aleksander Krag, et al.
Seminars in Immunology (2024) Vol. 71, pp. 101859-101859
Open Access | Times Cited: 15
The gut–brain axis underlying hepatic encephalopathy in liver cirrhosis
Xiaolong He, Mengyao Hu, Yi Xu, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial
Jasmohan S. Bajaj, Andrew Fagan, Edith Gavis, et al.
Journal of Hepatology (2025)
Closed Access | Times Cited: 1
Gut-derived systemic inflammation as a driver of depression in chronic liver disease
Victoria Kronsten, Thomas H. Tranah, Carmine M. Pariante, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 3, pp. 665-680
Open Access | Times Cited: 77
Cellular Pathogenesis of Hepatic Encephalopathy: An Update
Kaihui Lu
Biomolecules (2023) Vol. 13, Iss. 2, pp. 396-396
Open Access | Times Cited: 26
Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy
Carlo Airola, Andrea Severino, Serena Porcari, et al.
Antibiotics (2023) Vol. 12, Iss. 5, pp. 868-868
Open Access | Times Cited: 25
Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy via the gut-liver-brain axis
Ming Luo, Ruijuan Xin, Fang-Rui Hu, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 1, pp. 144-156
Open Access | Times Cited: 23
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis
Harry D Zacharias, Fady Kamel, Jaclyn Tan, et al.
Cochrane library (2023) Vol. 2023, Iss. 7
Closed Access | Times Cited: 22
Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases
Maja Thiele, Ida Falk Villesen, Lili Niu, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 345-359
Open Access | Times Cited: 12
Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers
Jonel Trebicka, Rubén Hernáez, Debbie L. Shawcross, et al.
Gut (2024) Vol. 73, Iss. 6, pp. 1015-1024
Open Access | Times Cited: 9
The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathy
Jasmohan S. Bajaj, Andrew Fagan, Edith Gavis, et al.
Hepatology Communications (2024) Vol. 8, Iss. 2
Open Access | Times Cited: 8
Research reviews and prospects of gut microbiota in liver cirrhosis: a bibliometric analysis (2001–2023)
Xiaofei Zhu, Ziyuan Zhou, Xiaxia Pan
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 7
Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)
César Jiménez, Meritxell Ventura‐Cots, Margarita Sala, et al.
Liver International (2022) Vol. 42, Iss. 5, pp. 1109-1120
Open Access | Times Cited: 36
The Double Game Played by Th17 Cells in Infection: Host Defense and Immunopathology
Marino Paroli, Rosalba Caccavale, Maria Teresa Fiorillo, et al.
Pathogens (2022) Vol. 11, Iss. 12, pp. 1547-1547
Open Access | Times Cited: 31
Gut microbiome-brain-cirrhosis axis
Maren L. Smith, James B. Wade, Jennifer T. Wolstenholme, et al.
Hepatology (2023) Vol. 80, Iss. 2, pp. 465-485
Closed Access | Times Cited: 21
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis
Jin-Xia Liu, Jane Macnaughtan, Annarein Kerbert, et al.
Gut (2024) Vol. 73, Iss. 7, pp. 1183-1198
Open Access | Times Cited: 5
Limitations of current techniques in clinical antimicrobial resistance diagnosis: examples and future prospects
Jack Hassall, Carmen H. Coxon, Vishal Patel, et al.
npj Antimicrobials and Resistance (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 5
Gut microbiome profiles to exclude the diagnosis of hepatic encephalopathy in patients with cirrhosis
Jasmohan S. Bajaj, Jacqueline G. O’Leary, Simona Jakab, et al.
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 5
Role of Intestinal Microbiome in Potentiating Inflammation and Predicting Outcomes in Alcohol-associated Cirrhosis
Sidsel Støy, Bernd Schnabl
Gastroenterology Clinics of North America (2025)
Closed Access
Page 1 - Next Page

Scroll to top